Member Info for Soupdragon78

Well done bloodninja, you might want to ask them to put the logo after your name that shows you are a premium member, then you could actually look at level 2.

Everyones gone quiet? Wonder why?

Our two quid buyer is happy today, is that you loading up Bloodninja?

Its been developed for a long time FX.

The way they operate is that Biocopea and PeptCell develop a new technique or product, they then spin off into a new company and that carries the product or technique forward.
So whilst the company is new, the development has been long in the making.

why are you looking forward to it?

FX, it was initial founded as Infirst, a spin off from the Peptcell group and Biocopea, and was a vehicle for the development of Flarin.
Once this was developed that was set up as a company in its own right leaving InFirst dormant.

In March this year they changed name to TRX. This ties in with when Oxilio signed the option agreement with NFX.

The news this week was the publicity launch.

From what I'm hearing their billionaire backer put 500k in.

Another name change cuddo?

Now the question is whether the traders who have jumped in over the past 24hrs hang on longer than Friday afternoon.

Let’s see if the 500k buyer is consistent, they’ve a usual been around in the first hour for the past three days

Good job has has 6.34% then

Thanks all.

Whilst the TRX news is indirect to NFX, it does help show that its likely there will be a milestone payment for NXP001 sometime around Q1 / Q2 next year given the news that Oxilio will be carrying out clinical trials then.

I don’t see it as in any way relating to 002 as that is being developed as inhaled, nor would I expect 004 as the company are clearly targeting selling the IP for that either back to the originator or to a generic, rather than undertaking any further development.

It's like the old days. Half of the TRX team were at NFX.

https://trxbiosciences.com/dev/teams/

Plus their collaborations are with Oxilio and Monument (of which Julian Gilbert is a director)

So, Dan Gooding is working alongside Oxilio to develop NXP001 for them.

But first up is Oxilio’s tumour-targeting drug.

“Oxilio is due to start a human clinical study in the first quarter of 2022 exploring an existing drug as a potential pan-cancer cure,” says John, “for people with untreatable cancers. But there are currently a series of issues to resolve, which we believe we can address with our technology.”

Oh look at who's involved.

https://www.cambridgeindependent.co.uk/business/trx-biosciences-presents-classic-cambridge-healthcare-breakt-9220933/

As I mentioned TRX before, Oxilio's connections coming to the fore.

https://www.oxilio.co.uk/news

No rumours on twitter, plus if you knew anything about the company you'd know we don't want anything to do with Chinese.

Think you missed an 's' off the 'big hitter' there FX.

lol, nothing changes, someone just bought 700k shares, held them for 40mins and sold for a few hundred quid profit.